Anticoagulant
FDA panel unanimously supports CV event risk reduction indication for icosapent ethyl
Direct oral anticoagulants confer fewer osteoporotic fractures in elderly vs. warfarin
Q&A: Guideline updates for nonvariceal GI bleeding
Meta-analysis: Dual therapy yields less bleeding than triple therapy in AF, CAD

Dual antithrombotic therapy conferred less bleeding but similar rates of mortality, stroke, nonfatal MI and stent thrombosis compared with triple antithrombotic therapy in patients with atrial fibrillation and concomitant CAD, according to a meta-analysis published in The American Journal of Cardiology.
Rivaroxaban does not show noninferiority to vitamin K antagonists in antiphospholipid syndrome

Rivaroxaban failed to demonstrate noninferiority to dose-adjusted vitamin K antagonists in patients with thrombotic antiphospholipid syndrome, and the agent even showed a nonsignificant doubling of the risk for recurrent thrombosis, according to results from an open-label, randomized, noninferiority trial published in the Annals of Internal Medicine.
Oral anticoagulation use increases for AF, stroke admissions decrease in Italy
Oral anticoagulation contraindication, increased mortality risk more likely in older patients with AF

Older patients with atrial fibrillation were more likely to have high bleeding risk contraindications with oral anticoagulation and higher mortality compared with patients who were not treated with oral anticoagulation and did not have contraindications, according to a observational, longitudinal analysis published in JACC: Clinical Electrophysiology.